Katerina Tatiana Galperine

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


61 publications

2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
2023
Cytomegalovirus in donors for fecal microbiota transplantation, the phantom menace?
Galpérine T., Engelmann I., Hantz S., Postil D., Dewilde A., Deplanque D., Martin R., Labreuche J., Lazrek M., Somers S. et al., 2023. PloS one, 18 (6) pp. e0287847. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_00FC93FBE728]
2022
Clostridioides difficile infection (CDI) epidemiology and patient characteristics in Switzerland.
Kampouri E., Filippidis P., Wölfle M., Taveira A., Badinski T., Croxatto A., Galperine T., Grandbastien B., Achermann Y., Guery B., 2022/08. Infectious diseases now, 52 (5) pp. 267-272. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D9587F593507]
 
Fecal microbiota transplantation: a review on current formulations in Clostridioides difficile infection and future outlooks.
Rakotonirina A., Galperine T., Allémann E., 2022/07. Expert opinion on biological therapy, 22 (7) pp. 929-944. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C90CE45CFC9]
Treatment and Outcomes of Clostridioides difficile Infection in Switzerland: A Two-Center Retrospective Cohort Study.
Filippidis P., Kampouri E., Woelfle M., Badinski T., Croxatto A., Galperine T., Papadimitriou-Olivgeris M., Grandbastien B., Achermann Y., Guery B., 2022/06/30. Journal of clinical medicine, 11 (13) p. 3805. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_694295A9316A]
 
SER-109 for Recurrent Clostridioides difficile Infection.
Benech N., Galperine T., Sokol H., French Group of Fecal Microbiota Transplantation, 2022/05/19. The New England journal of medicine, 386 (20) pp. 1956-1957. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_68D4114CEE5B]
2021
The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey.
Baunwall SMD, Terveer E.M., Dahlerup J.F., Erikstrup C., Arkkila P., Vehreschild M.J., Ianiro G., Gasbarrini A., Sokol H., Kump P.K. et al., 2021/10. The Lancet regional health. Europe, 9 p. 100181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_566EE2D61CC7]
Transplantation de microbiote fécal : de l’évidence aux réalités du terrain [Fecal microbiota transplantation: from the evidence to the realty of the field]
Ballif A., Gerber S., Carrez L., Audry M., Sadeghipour F., Mitouassiwou A., Croxatto A., Opota O., Prod'hom G., Henchoz S. et al., 2021/04/14. Revue medicale suisse, 17 (734) pp. 726-731. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6F57B9B68184]
2020
 
Impact de l'immunosuppression sur le traitement de l'infection à Clostridioides difficile
Kampouri E., Galpérine K.T., Croxatto A., Papadimitriou-Olivgeris M., Guery B., 2020/09. Médecine et Maladies Infectieuses, 50 (6) pp. S125.
[DOI][serval:BIB_4DF82C23778D]
 
Drug-Resistant Bacteremia after Fecal Microbiota Transplant.
Bleibtreu A., Kapel N., Galperine T., French Group of Faecal Microbiota Transplantation, 2020/05/14. The New England journal of medicine, 382 (20) p. 1961. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E156C4582A61]
Risk factors for candidemia: a prospective matched case-control study.
Poissy J., Damonti L., Bignon A., Khanna N., Von Kietzell M., Boggian K., Neofytos D., Vuotto F., Coiteux V., Artru F. et al., 2020/03/18. Critical care, 24 (1) p. 109. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A42B1C805146]
 
Favorable Outcome after Treatment Using Antibiotics and Hydroxychloroquine in a Patient with Tumor Necrosis Factor Receptor-associated Periodic Syndrome: A 7-Year Follow-Up
Galperine T., Lacout A., Marcy P. Y., Perronne C., 2020. J Glob Infect Dis, 12 (3) pp. 159-160.
[DOI][Pmid][serval:BIB_11F69C176ED3]
2019
 
Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity.
Mueller L., Masseron A., Prod'Hom G., Galperine T., Greub G., Poirel L., Nordmann P., 2019/11/21. Antimicrobial agents and chemotherapy, 63 (12) pp. e01111-19. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1ED69763A009]
 
Clostridioides difficile: diagnosis and treatments.
Guery B., Galperine T., Barbut F., 2019/08/20. BMJ, 366 pp. l4609. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1611587D02D4]
 
'A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae' - Author's reply.
Huttner B.D., Galperine T., Kapel N., Harbarth S., 2019/07. Clinical microbiology and infection, 25 (7) pp. 914-915. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D47D9E317652]
 
A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial
Huttner B. D., de Lastours V., Wassenberg M., Maharshak N., Mauris A., Galperine T., Zanichelli V., Kapel N., Bellanger A., Olearo F. et al., 2019/07. Clin Microbiol Infect, 25 (7) pp. 830-838.
[DOI][Pmid][serval:BIB_82180A9565B0]
 
Infectiologie sur mesure - 3. Transplantation de microbiote fécal : l’exemple du traitement de Clostridioides difficile [Customised infectiology - Fecal microbiota transplantation : following the Clostridioides difficile pathway]
Galperine T.K., Guery B., 2019/04/10. Revue medicale suisse, 15 (646) pp. 776-779. Peer-reviewed.
[Pmid][serval:BIB_3FB1130D6AA1]
 
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
Chirehwa M.T., McIlleron H., Wiesner L., Affolabi D., Bah-Sow O., Merle C., Denti P., RAFA team, 2019/01/01. The Journal of antimicrobial chemotherapy, 74 (1) pp. 139-148. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FFC55A03C7BB]
 
Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting
Barbut F., Galperine T., Vanhems P., Le Monnier A., Durand-Gasselin B., Canis F., Jeanbat V., Duburcq A., Alami S., Bensoussan C. et al., 2019. Health Qual Life Outcomes, 17 (1) p. 6.
[DOI][Pmid][serval:BIB_BD07FD73DD67]
2018
 
Practice guidelines for the management of adult community-acquired urinary tract infections
Caron F., Galperine T., Flateau C., Azria R., Bonacorsi S., Bruyere F., Cariou G., Clouqueur E., Cohen R., Doco-Lecompte T. et al., 2018/08. Med Mal Infect, 48 (5) pp. 327-358.
[DOI][Pmid][serval:BIB_4A898CC71400]
 
Exploring ways to improve CDI outcomes.
Galpérine T., Guery B., French Group of Fecal Microbiota Transplantation (GFTF), 2018/02. Medecine et maladies infectieuses, 48 (1) pp. 10-17. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9A97DB247AF]
2017
 
Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?
Robin C., Héquette-Ruz R., Guery B., Boyle E., Herbaux C., Galperine T., 2017/12. Medecine et maladies infectieuses, 47 (8) pp. 532-539. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA7184D0F60D]
 
Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
Pichenot M., Héquette-Ruz R., Le Guern R., Grandbastien B., Charlet C., Wallet F., Schiettecatte S., Loeuillet F., Guery B., Galperine T., 2017/08. Infection, 45 (4) pp. 425-431. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F4DFAB1200E]
 
Fecal Microbiota Transplantation: Do We Need Harmonization?
Galpérine T., Sokol H., Guery B., 2017/05/01. Clinical infectious diseases, 64 (9) p. 1292. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_56B3C177C24B]
Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
Baro E., Galperine T., Denies F., Lannoy D., Lenne X., Odou P., Guery B., Dervaux B., 2017. PloS one, 12 (1) pp. e0170258. Peer-reviewed.
[DOI][Pmid][serval:BIB_7215B307C47D]
2016
 
Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection
Faure E., Galperine T., Cannesson O., Alain S., Gnemmi V., Goeminne C., Dewilde A., Bene J., Lasri M., Lessore de Sainte Foy C. et al., 2016/11. Medicine (Baltimore), 95 (44) pp. e5226.
[DOI][Pmid][serval:BIB_C6D3872AE229]
 
Cefoxitin: An alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Mambie A., Vuotto F., Poitrenaud D., Weyrich P., Cannesson O., Dessein R., Faure K., Guery B., Galpérine T., 2016/06. Medecine et maladies infectieuses, 46 (4) pp. 215-219. Peer-reviewed.
[DOI][Pmid][serval:BIB_22D46DF377D1]
 
Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation.
Sokol H., Galperine T., Kapel N., Bourlioux P., Seksik P., Barbut F., Scanzi J., Chast F., Batista R., Joly F. et al., 2016/03. Digestive and liver disease, 48 (3) pp. 242-247. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4BCA770372A6]
 
Urinary Tract Infections in Older Men
Etienne M., Galperine T., Caron F., 2016. N Engl J Med, 374 (22) pp. 2191-2.
[DOI][Pmid][serval:BIB_72A75DB0E924]
2015
 
[Adequacy of antibiotic therapy for urinary tract infection in a Medical Department from the university hospital of Lille: A retrospective cohort study]
Deconinck L., Maillard H., Lemaitre M., Barbottin E., Bakhache E., Galperine T., Puisieux F., Hatron P. Y., Lambert M., 2015/11. Rev Med Interne, 36 (11) pp. 728-37.
[DOI][Pmid][serval:BIB_70A996A8ED17]
 
Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin. SPILF.).
Chidiac C., SPILF working group, 2015/09. Medecine et maladies infectieuses, 45 (9) pp. 348-373. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_57D758500800]
 
Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line
Aguado J. M., Anttila V. J., Galperine T., Goldenberg S. D., Gwynn S., Jenkins D., Noren T., Petrosillo N., Seifert H., Stallmach A. et al., 2015/06. J Hosp Infect, 90 (2) pp. 117-25.
[DOI][Pmid][serval:BIB_C819DBDA4759]
 
Ebola et autres, ces virus venus d’ailleurs [Ebola and others, those viruses coming from far away]
Guery B., Grandbastien B., Galpérine T., Faure K., 2015. Reanimation, 24 (Suppl 2) pp. 379-385. Peer-reviewed.
[DOI][Pmid][serval:BIB_FD8A2A326AA7]
2014
 
Biphasic hepatitis A with severe cholestasis and thrombocytopenic purpura in an HIV-1-infected male patient
Bani-Sadr F., Chakvetadze C., Galperine T., Lassel L., Bonnard P., Lependeven C., Roque-Afonso A. M., Pialoux G., 2014/02. Med Mal Infect, 44 (2) pp. 81-2.
[DOI][Pmid][serval:BIB_736CD299CA83]
 
Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors.
Samson M., Puéchal X., Devilliers H., Ribi C., Cohen P., Bienvenu B., Ruivard M., Terrier B., Pagnoux C., Mouthon L. et al., 2014. Autoimmunity Reviews, 13 (2) pp. 197-205.
[DOI][WoS][Pmid][serval:BIB_136EE4DA51CA]
2012
 
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
Petoumenos K., Worm S.W., Fontas E., Weber R., De Wit S., Bruyand M., Reiss P., El-Sadr W., Monforte A.D., Friis-Møller N. et al., 2012/10/10. Journal of the International AIDS Society, 15 (2) p. 17426. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_296941E03F01]
2010
 
Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort.
Encrenaz G., Bénard A., Rondeau V., Bonnet F., Lazaro E., Neau D., Dupon M., Dabis F., Mercié P., Chêne G. et al., 2010/04. Current HIV research, 8 (3) pp. 212-217. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_621D8477E2D9]
 
Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database.
Pagnoux C., Seror R., Henegar C., Mahr A., Cohen P., Le Guern V., Bienvenu B., Mouthon L., Guillevin L., French Vasculitis Study Group, 2010/02. Arthritis and rheumatism, 62 (2) pp. 616-626. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3CA4B608779A]
 
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.
Worm S.W., Friis-Møller N., Bruyand M., D'Arminio Monforte A., Rickenbach M., Reiss P., El-Sadr W., Phillips A., Lundgren J., Sabin C. et al., 2010. Aids, 24 (3) pp. 427-435.
[DOI][WoS][Pmid][serval:BIB_CD4F33D68D82]
 
Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen
Chakvetadze C., Bani-Sadr F., Le Pendeven C., Lescure F. X., Fontaine C., Galperine T., Slama L., Bonnard P., Mariot P., Soussan P. et al., 2010. Clin Infect Dis, 50 (8) pp. 1184-6.
[DOI][Pmid][serval:BIB_A0AFEB050ED4]
2009
 
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.
Podlekareva D.N., Mocroft A., Post F.A., Riekstina V., Miro J.M., Furrer H., Bruyand M., Panteleev A.M., Rakhmanova A.G., Girardi E. et al., 2009/11/27. AIDS, 23 (18) pp. 2485-2495. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5618F80EDF1D]
 
Plasma citrulline is a biomarker of enterocyte mass and an indicator of parenteral nutrition in HIV-infected patients
Crenn P., De Truchis P., Neveux N., Galperine T., Cynober L., Melchior J. C., 2009/09. Am J Clin Nutr, 90 (3) pp. 587-94.
[DOI][Pmid][serval:BIB_8B6D57071B05]
 
Recurrent bacteremia, a complication of cyanoacrylate injection for variceal bleeding: report of two cases and review of the literature.
Galperine T., Flateau C., Venon M.D., Lescure F.X., Béraud G., Said Ibrahim T., Delisle F., Durand F., Faure K., Pialoux G. et al., 2009. Case reports in medicine, 2009 p. 407053. Peer-reviewed.
[DOI][Pmid][serval:BIB_C9EC5FD33601]
2008
 
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
Monforte A.d., Abrams D., Pradier C., Weber R., Reiss P., Bonnet F., Kirk O., Law M., De Wit S., Friis-Møller N. et al., 2008/10. Aids, 22 (16) pp. 2143-2153. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDD3F0F60B9B]
 
Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort.
Loko M.A., Castera L., Dabis F., Le Bail B., Winnock M., Coureau G., Bioulac-Sage P., de Ledinghen V., Neau D., Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA), 2008/08. The American journal of gastroenterology, 103 (8) pp. 1973-1980. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_057441FFD0A7]
 
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin C.A., Sabin C.A., d'Arminio Monforte A., Friis-Moller N., Weber R., El-Sadr W.M., Reiss P., Kirk O., Mercie P. et al., 2008/04. Clinical Infectious Diseases, 46 (7) pp. 1101-1110. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_948D619B3F67]
 
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
D:A:D Study Group, Sabin C.A., Sabin C.A., Worm S.W., Weber R., Reiss P., El-Sadr W., Dabis F., De Wit S., Law M. et al., 2008/04. Lancet, 371 (9622) pp. 1417-1426. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CD0189BB5AEC]
2007
 
Drug-drug interactions with systemic antifungals in clinical practice
Depont F., Vargas F., Dutronc H., Giauque E., Ragnaud J. M., Galperine T., Abouelfath A., Valentino R., Dupon M., Hebert G. et al., 2007/11. Pharmacoepidemiol Drug Saf, 16 (11) pp. 1227-33.
[DOI][Pmid][serval:BIB_06B0DBC4A4A1]
 
Streptococcus canis infections in humans: retrospective study of 54 patients
Galperine T., Cazorla C., Blanchard E., Boineau F., Ragnaud J. M., Neau D., 2007/07. J Infect, 55 (1) pp. 23-6.
[DOI][Pmid][serval:BIB_E8B85E8D4EC3]
 
[Antibiotic therapy of osteoarticular infections in the adult]
Galperine T., Bernard L., 2007. Rev Prat, 57 (9) pp. 995-1002.
[Pmid][serval:BIB_9EEC8ECF350D]
 
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients
Delaugerre C., Mathez D., Peytavin G., Berthe H., Long K., Galperine T., de Truchis P., 2007. AIDS, 21 (9) pp. 1210-3.
[DOI][Pmid][serval:BIB_0B94F1482735]
2006
 
[Outpatient parenteral antimicrobial therapy (OPAT) in bone and joint infections]
Galperine T., Ader F., Piriou P., Judet T., Perronne C., Bernard L., 2006/03. Med Mal Infect, 36 (3) pp. 132-7.
[DOI][Pmid][serval:BIB_848D82DB8297]
2005
 
[Linezolid, the first oxazolidinone antibiotic]
Dutronc H., Bocquentin F., Galperine T., Lafarie-Castet S., Dupon M., 2005/09. Med Mal Infect, 35 (9) pp. 427-34.
[DOI][Pmid][serval:BIB_0212A990DDFA]
 
[Intolerance to and/or drug interactions of anti-HIV and anti-HVC therapy]
Galperine T., Merle C., de Truchis P., Bernard L., Perronne C., 2005/03. Med Mal Infect, 35 (3) pp. 135-40.
[DOI][Pmid][serval:BIB_C80C674F1D06]
2004
 
Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients
Neau D., Winnock M., Galperine T., Jouvencel A. C., Castera L., Legrand E., Tranchant E., Balestre E., Lacoste D., Ragnaud J. M. et al., 2004/05. HIV Med, 5 (3) pp. 171-3.
[DOI][Pmid][serval:BIB_C10F7D303144]
 
[The risk of rabies in France and the illegal importation of animals from rabid endemic countries]
Galperine T., Neau D., Moiton M. P., Rotivel Y., Ragnaud J. M., 2004. Presse Med, 33 (12 Pt 1) pp. 791-2.
[DOI][Pmid][serval:BIB_49EC990A73B7]
 
Cold bone defect on granulocytes labelled with technetium-99m-HMPAO scintigraphy: significance and usefulness for diagnosis and follow-up of osteoarticular infections
Galperine T., Dutronc H., Lafarie S., Neau D., Merino B., Cipriano G., Ragnaud J. M., Fernandez P., Basse-Cathalinat B., Dupon M., 2004. Scand J Infect Dis, 36 (3) pp. 209-12.
[DOI][Pmid][serval:BIB_80F81796FA37]
2003
 
Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients
Neau D., Jouvencel A. C., Legrand E., Trimoulet P., Galperine T., Chitty I., Ventura M., Le Bail B., Morlat P., Lacut J. Y. et al., 2003/09. J Med Virol, 71 (1) pp. 41-8.
[DOI][Pmid][serval:BIB_C68AA2A47A94]
 
T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin
Neau D., Galperine T., Legrand E., Pitard V., Neau-Cransac M., Moreau J. F., Ragnaud J. M., Dupon M., Fleury H., Lafon M. E., 2003/04. HIV Med, 4 (2) pp. 120-6.
[DOI][Pmid][serval:BIB_5E30A39D5AFD]
 
[Menstrual staphylococcal toxic shock is still a reality]
Galperine T., Neau D., Lina G., Richez C., Cazeau A. L., Dutronc H., Dupon M., Ragnaud J. M., 2003. Presse Med, 32 (24) pp. 1121-2.
[Pmid][serval:BIB_3E0762E2AA07]
2002
 
Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection
Trimoulet P., Neau D., Le Bail B., Rullier A., Winnock M., Galperine T., Legrand E., Schvoerer E., Dupon M., Ragnaud J. M. et al., 2002/06. J Med Virol, 67 (2) pp. 143-51.
[DOI][Pmid][serval:BIB_FD57F69C57EF]
 
CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment
Legrand E., Neau D., Galperine T., Trimoulet P., Moreau J. F., Pitard V., Lacut J. Y., Ragnaud J. M., Dupon M., Le Bail B. et al., 2002. J Infect Dis, 186 (3) pp. 302-11.
[DOI][Pmid][serval:BIB_5BD22996632F]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University